Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06959082 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer
A Phase 2 study of Head and Neck Cancer Squamous Cell Carcinoma, sponsored by VSPharmTech Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT06959082: Recruiting Phase 2 study of Head and Neck Cancer Squamous Cell Carcinoma, sponsored by VSPharmTech Co..
NCT06959082 is a Phase 2 study of Head and Neck Cancer Squamous Cell Carcinoma that is actively recruiting participants, run by VSPharmTech Co.. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06959082, a Phase 2 study of Head and Neck Cancer Squamous Cell Carcinoma, is actively recruiting participants, sponsored by VSPharmTech Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer.
Primary Outcome
The proportion of participants who achieve an ORR at 6 months and 12 months will be summarized with the 95% confidence interval on the mITT and PP samples.
Conditions Studied
Interventions
- DRUG Cisplatin
- RADIATION Radiation
- DRUG VS-101
Study Locations (3)
Connecticut
- Yale Cancer Center - New Haven
Kansas
- Cancer Center of Kansas - Wichita
New York
- NYU Langone Health - Manhattan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
What NCT06959082 shows while recruiting
NCT06959082 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Head and Neck Cancer Squamous Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT06959082 reports a single indexed study location in Connecticut, Kansas, New York.
Frequently Asked Questions
What is clinical trial NCT06959082 about?
NCT06959082 is a clinical study titled "Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer". This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer.
What is the current status of trial NCT06959082?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-03. Estimated completion is 2027-06.
What conditions does trial NCT06959082 study?
This clinical trial studies the following conditions: Head and Neck Cancer Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06959082?
The interventions under investigation include: Cisplatin (DRUG), Radiation (RADIATION), VS-101 (DRUG).
Who is sponsoring clinical trial NCT06959082?
This trial is sponsored by VSPharmTech Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06959082 being conducted?
This trial has 3 study locations across Connecticut, Kansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06959082's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia